"Lx®, the best choice for your ADC development program"

Read more


LinXis continues to employ chemists and scientists that provide a continuous flow of high impact articles ensuring prior-art and technological exposure of their developments.

A novel Platinum (II) Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin- F Conjugated Trastuzumab

January 2017

Sijbrandi JS, Merkul E, Muns JA, Waalboer DCJ, Adamzek K, Bolijn M, Montserrat V, Somsen GW, Hasselberg R, Steverink PJGM, Houthoff HJ, van Dongen GAMS.

Cancer Research January 15, 2017

Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model.

May 2015

Waalboer DC, Muns JA, Sijbrandi NJ, Schasfoort RB, Haselberg R, Somsen GW, Houthoff HJ, van Dongen GA.

ChemMedChem. 2015

Development of novel ADCs: conjugation of tubulysin-analogues to trastuzumab monitored by dual-radiolabeling.

October 2014

Cohen R, Vugts DJ, Visser GWM, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, Zanda M, Van Dongen GAMS.

Cancer Research. 2014

Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-modal fluorescent/PET imaging.

May 2013

Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GWM, Van Dongen GAMS.

Nature Protocols. 2013

Immuno-PET: shedding light on clinical antibody development.

August 2010

Van Dongen GAMS and Vosjan MJDW.

Cancer biotherapy & radiopharmaceuticals. 2010

Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

April 2010

Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, Van Dongen GAMS.

Nature Protocols. 2010